Kvantify raises €5M and says goodbye to founder

Kvantify, part of the NOME portfolio, has successfully raised €5 million to advance its work at the intersection of quantum computing and life sciences. The funding round, supported by both new and existing investors, will enable the company to strengthen its product offering, scale operations, and expand its commercial reach.

Founded with the vision of tackling some of the world’s most complex computational challenges, Kvantify has built a platform that applies proprietary, physics-based algorithms to drug discovery. By combining speed, accuracy and specialist expertise, the company helps streamline research pipelines, bringing pharmaceutical innovations closer to patients faster and more efficiently.

The new funding marks an important milestone in Kvantify’s journey and positions the company to consolidate its leading role in a rapidly evolving market. The company will continue to build on its strong technological foundation while advancing its strategic initiatives.

As part of this transition, co-founder Hans Henrik Knudsen has stepped back from his operational role after playing a central part in shaping Kvantify’s technology, fundraising, and customer relationships since the beginning. He remains a key shareholder and supporter of the company.

With this next chapter, Kvantify is well-positioned to drive forward the use of quantum computing in life sciences, opening new possibilities for drug discovery and making a tangible impact on healthcare and society.